PRINCETON, NJ, June 13, 2011 – Today, GE Healthcare Medical Diagnostics announced results of a study that evaluated the cardiopulmonary safety of Optison™ (Perflutren Protein-Type A Microspheres ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback